



Cédric Panje

Kontakt

Cédric Panje
Switzerland

T 0714942262
cedric.panje@kssg.ch

Bereiche

Radio-Onkologie

Funktion

Assistenzarzt/Assistenzärztin

Forschungsgebiet

Quality Assurance in der Radiotherapie des Prostatakarzinoms

Mitgliedschaften

SRO, DEGRO

Publikationen (31)

Panje C, Hayoz S, Eisterer W, Hess V, Thuss-Patience P, Schacher S, Dürr D, Wagner A, Girschikofsky M, Eboulet E, Stahl M, Ruhstaller T. Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. *Eur J Cancer* 2022; 177:186–193.

Vu E, Pratsinis M, Plasswilm L, Schmid H, Panje C, Betschart P. Radiotherapy or Surgery? Comparative, Qualitative Assessment of Online Patient Education Materials on Prostate Cancer. *Curr Oncol* 2021; 28:3420–3429.

Dennstädt F, Treffers T, Iseli T, Panje C, Putora P. Creation of clinical algorithms for decision-making in oncology: an example with dose prescription in radiation oncology. *BMC Med Inform Decis Mak* 2021; 21:212.

Ostheimer C, Dobiasch S, Arnold C, Oertel M, Haussmann J, Gauer T, Goy Y, Suess C, Ziegler S, Panje C, Baues C, Trommer M, Skripcak T, Billiet C, Thieme A, Kaul D, Mäurer M, Ebert N, Schmitt D, Krug D, Baumann R, Henkenberens C, Giordano F, Sautter L, López G, Fleischmann D, Niyazi M, Käsmann L, Medenwald D. Correction to: Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. *Strahlenther Onkol* 2021; 197:560–561.

Achard V, Panje C, Engeler D, Zilli T, Putora P. Localized and Locally Advanced Prostate Cancer: Treatment Options. *Oncology* 2021; 99:413–421.

Barbier M, Pardo E, Panje C, Gautschi O, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. *Eur J Health Econ* 2021; 22:669–677.

Ostheimer C, Dobiasch S, Arnold C, Oertel M, Haussmann J, Gauer T, Goy Y, Suess C, Ziegler S, Panje C, Baues C, Trommer M, Skripcak T, Billiet C, Thieme A, Kaul D, Mäurer M, Ebert N, Schmitt D, Krug D, Baumann R, Henkenberens C, Giordano F, Sautter L, López G, Fleischmann D, Niyazi M, Käsmann L, Medenwald D. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. *Strahlenther Onkol* 2021; 197:385–395.

Iseli T, Plasswilm L, Sirén C, Schmidt B, Rothermundt C, Hundsberger T, Glatzer M, Panje C, Fischer G, Putora P. Insular Decision Criteria in Clinical Practice: Analysis of Decision-Making in Oncology. *Oncology* 2020; 98:438–444.

Panje C, Schwenkglenks M, Gautschi O, Plasswilm L, Aebersold D, Dedes K, Lorez M, Pardo E, Barbier M, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. *Ann Oncol* 2020; 31:501–506.

Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. *Swiss Med Wkly* 2019; 149:w20170.

Panje C, Putora P, Hundsberger T, Hottinger A, Roelcke U, Pesce G, Herrmann E, Matter-Walstra K. Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study. *Swiss Med Wkly* 2019; 149:w20153.

Maas O, Weidner S, Walter M, Schaefer N, Rottenburger C, Kneifel S, Kamel M, Haldemann A, Giovanella L, Engel-Bicik I, Brühlmeier M, Blautzik J, Panje C, Maas M, Forrer F, Putora P. Variations in radioiodine ablation: decision-making after total thyroidectomy. *Eur J Nucl Med Mol Imaging* 2019

Panje C, Zwahlen D, Veas H, Reuter C, Pesce G, Papachristofilou A, Kaouthar K, Herrera F, Gomez S, Garcia Schüler H, Brouwer K, Arnold W, Pra A, Zilli T, Putora P. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. *Radiat Oncol* 2019; 14:177.

Panje C, Plasswilm L, Ruhstaller T, Gerard M, Hawle H, Schacher S, Henke G, Meier U, Garcia Schüler H, Herrmann E, Baracos V, Hayoz S, Höng L, Swiss Group for Clinical Cancer Research (SAKK). Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. *Radiat Oncol* 2019; 14:166.

Glatzer M, Panje C, Sirén C, Cihoric N, Putora P. Decision Making Criteria in Oncology. *Oncology* 2018; Sep 18:1-9

Hirschmann A, Lupatsch J, Schwenkglenks M, Panje C, Matter-Walstra K, Espeli V, Dedes K, Siano M, Swiss Group of Clinical Cancer Research (SAKK). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. *Oral Oncol* 2018; 87:104-110.

Glatzer M, Panje C, Sirén C, Cihoric N, Putora P. Decision Making Criteria in Oncology. *Oncology* 2018:1-9.

Panje C, Lupatsch J, Plasswilm L, Aebersold D, Siano M, Gautschi O, Schwenkglenks M, Matter-Walstra K, Dedes K, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). *Radiother Oncol* 2018; 129:257-263.

Jiang L, Tang Q, Panje C, Nie H, Zhao G, Shi H. Assessment of pancreatic colloid carcinoma using F-FDG PET/CT compared with MRI and enhanced CT. *Oncol Lett* 2018; 16:1557-1564.

Panje C, Glatzer M, Sirén C, Plasswilm L, Putora P. Treatment Options in Oncology. *JCO Clin Cancer Inform* 2018; 2:1-10.

Käsmann L, Mäurer M, Panje C, Rosenbrock J, Sautter L, Schmitt D, Süß C, Thieme A, Trommer-Nestler M, Ziegler S, Ebert N, Medenwald D, Ostheimer C, Krug D, Kloock L, Kaul D, Niyazi M, Blanck O, Baues C, Baumann R, Dobiasch S, Eze C, Fleischmann D, Gauer T, Giordano F, Goy Y, Hausmann J, Henkenberens C, Young DEGRO Trial Group. Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review. *Strahlenther Onkol* 2017; 194:79-90.

Panje C, Glatzer M, von Rappard J, Rothermundt C, Hundsberger T, Zumstein V, Plasswilm L, Putora P. Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis. *BMC Med Res Methodol* 2017; 17:123.

Dal Pra A, Engeler D, Zwahlen D, Veas H, Reuter C, Pesce G, Papachristofilou A, Kaouthar K, Herrera F, Gomez S, Glatzer M, Garcia H, Brouwer K, Arnold W, Zilli T, Panje C, Putora P. Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy : A national survey on patterns of practice. *Strahlenther Onkol* 2017; 194:9-16.

Panje C, Dal Pra A, Zilli T, R Zwahlen D, Papachristofilou A, Herrera F, Matzinger O, Plasswilm L, Putora P. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice. *Strahlenther Onkol* 2015; 191:778-86.

Panje C, Panje T, Putora P, Kim S, Haile S, Aebersold D, Plasswilm L. Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience. *Radiat Oncol* 2015; 10:47.

Putora P, Panje C, Hundsberger T, van Leyen K, Plasswilm L, Früh M. Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). *Clin Exp Metastasis* 2015; 32:143-9.

Putora P, Panje C, Papachristofilou A, Pra A, Hundsberger T, Plasswilm L. Objective consensus from decision trees. *Radiat Oncol* 2014; 9:270.

Panje C, Wang D, Willmann J. Ultrasound and microbubble-mediated gene delivery in cancer: progress and perspectives. *Invest Radiol* 2013; 48:755-69.

Panje C, Wang D, Pysz M, Paulmurugan R, Ren Y, Tranquart F, Tian L, Willmann J. Ultrasound-mediated gene delivery with cationic versus neutral microbubbles: effect of DNA and microbubble dose on in vivo transfection efficiency. *Theranostics* 2012; 2:1078-91.

Wang D, Panje C, Pysz M, Paulmurugan R, Rosenberg J, Gambhir S, Schneider M, Willmann J. Cationic versus neutral microbubbles for ultrasound-mediated gene delivery in cancer. *Radiology* 2012; 264:721-32.

Pysz M, Foygel K, Panje C, Needles A, Tian L, Willmann J. Assessment and monitoring tumor vascularity with contrast-enhanced ultrasound maximum intensity persistence imaging. *Invest Radiol* 2011; 46:187-95.

Projekte (3)

DOSIS RCT_Dose-intensified-Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastasis versus Conventional Therapy: A Randomized Controlled Trial

Klinische Forschung - 03.07.2019 - 03.07.2024

Automatisch geschlossen

SAKK 08/15 PROMET

Klinische Forschung - 27.09.2017 - 07.10.2030

Laufend

Impact of Sarcopenia in Curative Trimodality Therapy for Esophageal Cancer

Klinische Forschung - 13.01.2015 - 31.12.2015

Automatisch geschlossen

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch